<document>
<page1>
<text font_bg = '255,255,255'>
Page 1 of 11 </text>
<text font_bg = '255,255,255'>
 <bold> mae </bold> <bold> cet </bold> <bold> #: </bold>From Visit On: 04/11/16  <bold> Office </bold> <bold> Visit </bold></text>
<text font_bg = '244,250,255'>
 <bold> 4/11/2016 </bold> <bold> Pe </bold> <bold> | </bold> <bold> MRN: </bold> <bold> 1388862 </bold></text>
<text font_bg = '255,255,255'>
 <bold> Reason </bold>for Visit  <bold> Heme/Onc </bold> <bold> Care </bold></text>
<table>
<tr>New Patient


</tr>
<tr>Reason for Visit History

</tr>
<tr>AVS Reports


</tr>
<tr>Date/Time Report Action User


</tr>
<tr>4/11/2016 12:09 After Visit Summary Printed Michelle Norris


</tr>
<tr>PM


</tr>
<tr>Most recent update: 4/11/2016 10:44 AM by


</tr>
<tr>Vital Signs Erica Newton


</tr>
<tr>BP Pulse Temp(Src) Resp Ht Wt


</tr>
<tr>428/102 98 36.9 °C (98.4 °F) 20 185.4 cm (72.99") 73.483 kg (162 Ib)


</tr>
<tr>mmHg (Oral)


</tr>
<tr>BMI SpO2


</tr>
</table>
<text font_bg = '255,255,255'>
21.38 kg/m2 94% </text>
<text font_bg = '255,255,255'>
 <bold> Progress </bold> <bold> Notes </bold>Sherin Fetouh,  <bold> MD </bold> <bold> at </bold>04/11/16 1040 Status: Signed Date of Service: 4/11/2016 </text>
<text>
 <bold> Subjective: </bold></text>
<text font_bg = '255,255,255'>
 <bold> Past </bold> <bold> History: </bold>He has chemotherapy induced polyneuropathy due  <bold> to </bold>oxalipatin and hand and foot syndrome due  <bold> to </bold></text>
<text font_bg = '255,255,255'>
capecitabine.He received in addition epirubicin. He  <bold> was </bold>diagnosed with adenocarcinoma of  <bold> GE </bold>junction, T3N2 with removal of 30+ nodes and Roux  <bold> en </bold>Y surgery March 2013 Mayo Clinic. They diagnosed the hand  <bold> and </bold>foot syndrome and CIP neuropathy. He has been  <bold> a </bold>diabetic (type 2) for the past 10-15 years without any paresthesia. March 2013 he received chemotherapy, palms and soles began peeling, cracking of skin and developed ulcerations in both feet and  <bold> R </bold>hand. He underwent chemorx  <bold> 9 </bold>weeks. He developed buzzing  <bold> and </bold>tingling in the hands and dorsal feet after the hand and foot syndrome. He has noted numbness of last  <bold> 2 </bold>fingers of L hand in year. He feels  <bold> weak </bold>all  <bold> over </bold>but not focally. He is followed by  <bold> a </bold> <bold> wound </bold>specialist for 3 L foot ulcerations (required amputation March 2014 of the  <bold> 5th </bold>metatarsal) due  <bold> to </bold>osteomyelitis. He also has ulcerations under large  <bold> toe </bold> <bold> on </bold>L. He had  <bold> a </bold>deep ulceration palmar R index finger and several smaller  <bold> ones </bold>in both hands. He  <bold> uses </bold>hand lotion  <bold> bid </bold>and neuropathic topical  <bold> cream </bold>with amitryptiline. He  <bold> uses </bold> <bold> a </bold>scooter to relieve pressure  <bold> on </bold> <bold> feet </bold>for last year. Patient had  <bold> a </bold> <bold> BKA </bold>in September 2015, due  <bold> to </bold> <bold> an </bold>ankle fracture and subsequent infection. </text>
<text font_bg = '255,255,255'>
 <bold> History </bold> <bold> of </bold> <bold> Present </bold> <bold> Illness </bold>is  <bold> a </bold>57 y.o. male referred  <bold> to </bold> <bold> our </bold>clinic by Dr. Kiene for  <bold> severe </bold>CIPN, related  <bold> to </bold>gastric  <bold> cancer </bold></text>
<text font_bg = '255,255,255'>
lagnosed  <bold> and </bold>treated in 2013 with Oxalaplatin. Patient has followed with Dr. April McVey in the Neurology department. Patient is  <bold> on </bold>Gabapentin 800mgQID, Cymbalta 60mg Daily, Nortriptyline 100mg QHS, Alpha Lipoic Acid 600mg  <bold> ER </bold>tablet daily, and is using  <bold> a </bold>compounding  <bold> cream </bold>with Amitriptyline 2%, Ketamine 5%, and Lidocaine 5%. He also takes Oxydocone 7.5/325 mg tablets, 4 tablets per day. He  <bold> was </bold>started  <bold> on </bold>Nucynta 250mg Q12H, prescribed by Dr. Kosa at NKCH Neurology Department. He  <bold> was </bold>transferred  <bold> to </bold>Meritas Pain Management with Dr. Gau, who  <bold> was </bold>transferred  <bold> to </bold>the Mayo Clinic. Dr. Dimachkie performed EMG/NCS in January 2015 and found 1) moderate  <bold> to </bold> <bold> severe </bold>axonal neuropathy 2) bilateral ulnar neuropathies  <bold> at </bold>the elbows with conduction block  <bold> R </bold>elbow 3) active and chronic denervation in  <bold> R </bold>FDI, triceps and deltoid. </text>
<text font_bg = '255,255,255'>
Review of Systems </text>
<text font_bg = '255,255,255'>
 <bold> PE </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 1 of 11 </text>
</page1>
<page2>
<text font_bg = '255,255,255'>
Page 2 of 11 </text>
<text font_bg = '255,255,255'>
Constitutional: Current everyday smoker. HENT: Negative. Eyes: Negative. Respiratory: Negative. Cardiovascular: Negative. Gastrointestinal: Negative. Genitourinary: Negative. Musculoskeletal:  <bold> Left </bold> <bold> BKA </bold>due  <bold> to </bold> <bold> an </bold>ankle fracture. Gait abnormality. Skin: Negative. Neurological: Severe CIPN. Hematological: Negative. Psychiatric/Behavioral: Negative. </text>
<text font_bg = '255,255,255'>
 <bold> Past </bold> <bold> Medical </bold>History Diagnosis Date  <bold> * </bold>Cancer (HCC)  <bold> ¢ </bold>Neuropathy  <bold> * </bold>Sleep disorder </text>
<text font_bg = '255,255,255'>
Past Surgical History Procedure Laterality Date  <bold> ¢ </bold>Hx shoulder surgery Right  <bold> and </bold>left  <bold> ¢ </bold>Biceps tendon repair  <bold> ¢ </bold>Hx lumbar fusion  <bold> * </bold>Stomach surgery gastroectomy; roux-n-y  <bold> ¢ </bold>Prdebridement, skin, sub-q tissue,muscle,bone </text>
<table>
<tr>osteomyelitis

</tr>
<tr>Family History

</tr>
<tr>Problem Relation Age of Onset

</tr>
<tr>* Cancer Mother

</tr>
<tr>* Cancer Sister

</tr>
<tr>* Cancer Brother

</tr>
<tr>History

</tr>
<tr>Social History

</tr>
<tr>¢ Marital Status: Married

</tr>
<tr>Spouse Name: N/A

</tr>
<tr>Number of Children: N/A

</tr>
<tr>¢ Years of Education: N/A

</tr>
<tr>Social History Main Topics

</tr>
<tr>* Smoking status: Former Smoker

</tr>
<tr>Quit date: 01/29/2009

</tr>
<tr>* Smokeless tobacco: Not on file

</tr>
<tr>¢ Alcohol Use: Not on file

</tr>
<tr>¢ Drug Use: Not on file

</tr>
<tr>* Sexual Activity: Not on file

</tr>
<tr>Other Topics Concern

</tr>
<tr>¢ Not on file


</tr>
</table>
<text font_bg = '238,238,238'>
Social History Narrative </text>
<text font_bg = '255,255,255'>
 <bold> No </bold>Known Allergies </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 2 of 11 </text>
</page2>
<page3>
<text>
Page 3 of 11 </text>
<text>
 <bold> ¢ </bold>L. ACIDOPHILUS/BIFID. ANIMALIS (CHEWABLE Take by mouth twice daily.  <bold> 3 </bold> <bold> am </bold>and  <bold> 3 </bold>pm PROBIOTIC PO)  <bold> ¢ </bold>L. RHAMNOSUS GG/INULIN (CULTURELLE Take by mouth. PROBIOTICS PO)  <bold> ¢ </bold>methadone (DOLOPHINE; METHADOSE) 10 mg Take  <bold> 1 </bold>tab po three times  <bold> a </bold>day </text>
<table>
</table>
<table>
<tr>tablet

</tr>
<tr>¢ other medication 120GM amitriptyline2%, Keta 5%, Lido 5%,

</tr>
<tr>Vanicream twice daily

</tr>
<tr>* oxyCODONE (ROXICODONE) 5 mg tablet Take 1 Tab by mouth every 6 hours as needed for

</tr>
<tr>Pain

</tr>
<tr>* oxyCODONE-acetaminophen (PERCOCET; Take 1 Tab by mouth every 6 hours as needed

</tr>
<tr>ENDOCET) 10-325 mg tablet Earliest Fill Date: 9/21/15

</tr>
<tr>Simethicone 125 mg tab Take by mouth.


</tr>
</table>
<text>
venlafaxine (EFFEXOR) 37.5 mg tablet Take 37.5 mg by mouth twice daily. </text>
<text>
There  <bold> were </bold>no vitals  <bold> filed </bold>for this visit. There  <bold> is </bold> <bold> no </bold>weight on file  <bold> to </bold>calculate  <bold> BMI. </bold></text>
<text>
Physical Exam Ortho Exam </text>
<text>
 <bold> Physical </bold> <bold> Exam </bold>Constitutional: appears well-developed.  <bold> No </bold>distress. </text>
<text>
Head: Normocephalic and atraumatic. Eyes: Conjunctivae  <bold> are </bold>normal.  <bold> No </bold>scleral icterus. Neck: Normal range of motion. Neck supple. Cardiovascular: Normal rate and regular rhythm. Pulmonary/Chest:  <bold> Effort </bold>normal.  <bold> No </bold>respiratory distress. Abdominal: Soft. There  <bold> is </bold> <bold> no </bold>tenderness. Skin: Skin  <bold> is </bold> <bold> warm </bold>and dry. MSK: Atrophy of the  <bold> left </bold>calf muscle, intrinsic hand muscle wasting. Left 5th toes amputated, with significant abnormality of the  <bold> left </bold>later foot,  <bold> at </bold>the arch. Well-healed right  <bold> BKA </bold>residual limb, with  <bold> a </bold>very small, scabbed  <bold> wound </bold>the size of  <bold> a </bold>pin point. 10-ply socks removed from the residual limb. Neuro: CNII-XII grossly intact. AxOx3. Sensation  <bold> to </bold>light touch diminished in  <bold> a </bold>stocking-glove distribution, in the BUE/BLE. Impaired gait with  <bold> R </bold> <bold> BKA </bold>prosthetic, with  <bold> a </bold>SPC. Proprioception intact at the b/l ankles, and impaired  <bold> at </bold>the b/I great toes. Psychiatric: normal mood  <bold> and </bold>affect. Behavior  <bold> is </bold>normal. </text>
<text>
 <bold> GEE </bold> <bold> «Was </bold> <bold> seen </bold>today for heme/onc  <bold> care </bold>and  <bold> new </bold>patient. </text>
<text>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 3 of 11 </text>
</page3>
<page4>
<text font_bg = '255,255,255'>
Page 4 of 11 </text>
<text font_bg = '255,255,255'>
Diagnoses and associated orders for this visit: </text>
<text font_bg = '255,255,255'>
Neuropathy  <bold> due </bold> <bold> to </bold>oxaliplatin  <bold> - </bold>Physical Therapy Order  <bold> & </bold>Schedule  <bold> ** </bold>Requires Separate Form** </text>
<text font_bg = '255,255,255'>
Tobacco abuse  <bold> - </bold>Physical Therapy Order  <bold> & </bold>Schedule  <bold> ** </bold>Requires Separate Form** </text>
<text font_bg = '255,255,255'>
Tobacco abuse counseling  <bold> - </bold>Physical Therapy Order  <bold> & </bold>Schedule  <bold> ** </bold>Requires Separate Form** </text>
<text font_bg = '255,255,255'>
Vasculopathy  <bold> - </bold>Physical Therapy Order  <bold> & </bold>Schedule  <bold> ** </bold>Requires Separate Form** </text>
<text font_bg = '255,255,255'>
Dehydration  <bold> - </bold>Physical Therapy Order  <bold> & </bold>Schedule  <bold> ** </bold>Requires Separate Form** </text>
<text font_bg = '255,255,255'>
 <bold> Orthostatic </bold>hypotension  <bold> - </bold>Physical Therapy Order  <bold> & </bold>Schedule  <bold> ** </bold>Requires Separate Form** </text>
<text font_bg = '255,255,255'>
Neuralgia  <bold> - </bold>Physical Therapy Order  <bold> & </bold>Schedule  <bold> ** </bold>Requires Separate Form** </text>
<text font_bg = '255,255,255'>
 <bold> Skin </bold>sensation disturbance  <bold> - </bold>Physical Therapy Order  <bold> & </bold>Schedule  <bold> ** </bold>Requires Separate Form** </text>
<text font_bg = '255,255,255'>
Complete  <bold> below </bold> <bold> knee </bold>amputation  <bold> of </bold>right lower extremity,  <bold> initial </bold>encounter (HCC)  <bold> - </bold>Physical Therapy Order  <bold> & </bold>Schedule  <bold> ** </bold>Requires Separate Form** </text>
<text font_bg = '255,255,255'>
 <bold> Gait </bold>abnormality  <bold> - </bold>Physical Therapy Order  <bold> & </bold>Schedule  <bold> ** </bold>Requires Separate Form** </text>
<text font_bg = '255,255,255'>
Polyneuropathy due  <bold> to </bold>drug (HCC) </text>
<text font_bg = '255,255,255'>
 <bold> Other </bold>Orders  <bold> - </bold>buprenorphine HCI (BELBUCA) 75 mcg film; Place 75 mcg inside cheek (side of mouth) every 12 hours. </text>
<text font_bg = '255,255,255'>
Assessment and Plan: </text>
<text font_bg = '255,255,255'>
Patient is  <bold> a </bold>pleasant 57 yo male with  <bold> a </bold>history of gastric cancer diagnosed and treated in 2013 with Oxaloplatin, who developed  <bold> severe </bold>CIPN. Patient also with  <bold> a </bold>history of  <bold> DM </bold>type II and  <bold> was </bold> <bold> a </bold>former smoker. H&P is consistent with: </text>
<text font_bg = '255,255,255'>
CIPN,  <bold> severe </bold> <bold> . </bold>High fall risk  <bold> . </bold>Impaired gait and balance  <bold> . </bold>Neuropathic pain  <bold> . </bold>Prior history of  <bold> DM </bold>type 2 Tobaccoism RBKA  <bold> . </bold>Left foot deformity ONMAONRWN </text>
<text>
CIPN,  <bold> severe </bold> <bold> . </bold>High fall risk  <bold> . </bold>Impaired gait and balance  <bold> . </bold>Neuropathic pain  <bold> . </bold>Prior history of  <bold> DM </bold>type 2 Tobaccoism RBKA  <bold> . </bold>Left foot ONMAONRWN </text>
<text font_bg = '255,255,255'>
PLAN: 1. Lifestyle: Patient provided  <bold> a </bold>home safety checklist, to help reduce his fall risk. Patient to  <bold> use </bold> <bold> a </bold>SPC at all time. Patient  <bold> was </bold>counseled regarding smoking cessation. Patient  <bold> was </bold>refitted for  <bold> a </bold> <bold> new </bold>prosthetic at the Leavenworth VA, through Horizons at NKCH. Dr. Kiene at the Leavenworth VA will follow up on the script. Patient also provided contact information for  <bold> a </bold>Podiatrist, Stephanie Jameson, at KC Foot and Ankle. Patient may also contact Dr. Fines,  <bold> a </bold>Podiatrist, at NKCH. </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 4 of 11 </text>
</page4>
<page5>
<text>
Page 5 of 11 </text>
<text>
2. Medications: Patient will continue the Gabapentin 800mg QID, Cymbalta 60mg Daily, Alpha Lipoic Acid 600mg  <bold> ER </bold>Daily, Oxycodone 7.5-325mg  <bold> Q6H </bold>prn,  <bold> max </bold>4 tabs  <bold> per </bold>day, Nortriptyline 50mg QHS, and compounding cream. We will start Belbuca 75mcg film  <bold> to </bold>the inside of the cheek, Q12H. 3. Therapy: Prescribed PT for impaired gait, balance, and  <bold> new </bold>prosthetic training. Also, will evaluate for  <bold> DME. </bold> <bold> New </bold>script provided today for NKCH. 4. Diagnostics:  <bold> EDX </bold>completed by Dr. Dimachke in January 2015, showing  <bold> severe </bold>axonal peripheral neuropathy. 5. Interventions:  <bold> Not </bold>indicated  <bold> at </bold>this time. 6. Follow up in 4 weeks. </text>
<text>
Leslie S. Cavazos,  <bold> MD </bold>Cancer Rehabilitation Fellow </text>
<text>
 <bold> ATTESTATION </bold></text>
<text>
 <bold> | </bold>personally performed the key portions of the  <bold> E/M </bold>visit, discussed  <bold> case </bold>with resident/fellow and  <bold> concur </bold>with the resident's/fellow's documentation of history, physical exam, assessment, and treatment plan unless otherwise noted  <bold> as </bold>it pertains  <bold> to </bold>my  <bold> assessment </bold>and plan. </text>
<text>
 <bold> Staff </bold> <bold> name: </bold>Sherin Fetouh,  <bold> MD </bold>4/21/2016 </text>
<text>
Revision History re) </text>
<text>
Transcription </text>
<text>
Type ID Date and Time Author Patient Auth  <bold> to </bold>321Z04D_02BP9SGR8000EVM 4/11/2016 12:00  <bold> AM </bold>SCANNED DOCUMENT Share/Leave  <bold> Med </bold>Info Signed by SCANNED DOCUMENT on 04/12/16  <bold> at </bold>1513 </text>
<text>
Display only: Transcription (321Z04D_O2BP9SGR8000EVM) on 4/11/2016 12:00  <bold> AM </bold>by SCANNED DOCUMENT  <bold> Goals </bold> <bold> (2 </bold> <bold> Years </bold> <bold> of </bold> <bold> Data) </bold> <bold> as </bold> <bold> of </bold> <bold> 4/11/16 </bold></text>
<table>
<tr>None

</tr>
<tr>Reviewed: 5/22/2016 12:25 PM by Sherin

</tr>
<tr>Problem List Fetouh, MD

</tr>
<tr>Priority Class Noted Last Modified

</tr>
<tr>Hand and foot syndrome after chemotherapy 2/6/2015 2/6/2015 by

</tr>
<tr>April McVey

</tr>
<tr>Neuropathy due to oxaliplatin 2/6/2015 2/6/2015 by

</tr>
<tr>April McVey

</tr>
<tr>Bilateral ulnar neruopathies 2/6/2015 2/6/2015 by

</tr>
<tr>April McVey

</tr>
<tr>Medical Past Medical History Date Comments Source

</tr>
<tr>as of 4/11/2016 Cancer (HCC) [C80.1] Provider

</tr>
<tr>Neuropathy [G62.9] Provider

</tr>
<tr>Sleep disorder [G47.9] Provider


</tr>
</table>
<text>
 <bold> PE </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 5 of 11 </text>
</page5>
<page6>
<text>
Page 6 of 11 </text>
<table>
<tr>Surgical Past Surgical History Laterality Date Comments Source

</tr>
<tr>as of HX SHOULDER SURGERY [HX334] Right and left Provider

</tr>
<tr>4/11/2016

</tr>
<tr>BICEPS TENDON REPAIR [SHX566] Provider

</tr>
<tr>HX LUMBAR FUSION [SHX111] Provider

</tr>
<tr>STOMACH SURGERY [SHX791] gastroectomy; Provider

</tr>
<tr>roux-n-y

</tr>
<tr>PR DEBRIDEMENT BONE MUSCLE osteomyelitis Provider


</tr>
</table>
<text>
&/FASCIA 20 SQ CM/< [11044] </text>
<table>
<tr>Family Problem Relation Name Age of Onset Comments Source


</tr>
<tr>as of 4/11/2016 Cancer Mother Provider

</tr>
<tr>Cancer Sister Provider

</tr>
<tr>Cancer Brother Provider


</tr>
</table>
<text>
Family  <bold> Status </bold>**None** </text>
<table>
<tr>as of 4/11/2016

</tr>
<tr>Tobacco Use Smoking Source Types Packs/day Years Comments Smoking Smoking Smokeless Smokeless

</tr>
<tr>Status Used Start Quit Date Tobacco Tobacco

</tr>
<tr>Date Status Quit Date

</tr>
<tr>as of Former Provider 0.0 0.0 1/29/2009 Unknown

</tr>
<tr>4/11/2016 Smoker

</tr>
<tr>Alcohol Use Alcohol Use Source Drinks/Week Alcohol/(Wk Comments

</tr>
<tr>as of 4/11/2016 Not Asked Provider

</tr>
<tr>Drug Use Drug Use Source Types Frequency Comments

</tr>
<tr>as of 4/11/2016 Not Asked Provider 0.00

</tr>
<tr>Sexual Activity Sexually Active Source Birth Control Partners Comments

</tr>
<tr>as of 4/11/2016 Not Asked Provider

</tr>
<tr>Social ADL ADL Question Response Comments Source

</tr>
<tr>as of 4/11/2016 **None**

</tr>
<tr>Social Doc **None**

</tr>
<tr>as of 4/11/2016

</tr>
<tr>Occupational **None**

</tr>
<tr>as of 4/11/2016

</tr>
<tr>Socioeconomic Marital Status Spouse Name Num of Children Years Education Source

</tr>
<tr>as of 4/11/2016 Married

</tr>
<tr>Preferred Ethnicity Race

</tr>
<tr>Language

</tr>
<tr>ENGLISH Non Hispanic, Latino or White or Caucasian


</tr>
</table>
<text>
Spanish Origin </text>
<text>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 6 of 11 </text>
</page6>
<page7>
<text font_bg = '255,255,255'>
Page 7 of 11 </text>
<table>
<tr>Birth **None**


</tr>
<tr>Advance Q A Comments


</tr>
<tr>Directives


</tr>
<tr>Status


</tr>
<tr>as of 4/11/2016 Do You Have Living Will Or No No on 4/11/2016

</tr>
<tr>Advance Directive?


</tr>
<tr>Past Q A Comments


</tr>
</table>
<text font_bg = '255,255,255'>
Hospitalizations  <bold> 7 </bold> <bold> as </bold> <bold> of </bold> <bold> 4/11/2016 </bold>Past Hospitalizations? </text>
<text font_bg = '255,255,255'>
 <bold> Additional </bold>History </text>
<text font_bg = '255,255,255'>
History Last reviewed in  <bold> this </bold>visit by  <bold> Erica </bold> <bold> Newton </bold> <bold> on </bold>4/11/2016  <bold> at </bold>10:44  <bold> AM </bold>Sections Reviewed Tobacco </text>
<text font_bg = '255,255,255'>
History Last  <bold> Reviewed </bold>by  <bold> D'Mesha </bold>Jefferson,  <bold> MA </bold> <bold> on </bold> <bold> 5/10/2016 </bold> <bold> at </bold>10:34  <bold> AM </bold></text>
<text font_bg = '255,255,255'>
Tobacco  <bold> use </bold></text>
<text font_bg = '255,255,255'>
Last reviewed 5/10/2016 </text>
<text font_bg = '255,255,255'>
Visit Diagnoses  <bold> and </bold>Associated Orders </text>
<text font_bg = '255,255,255'>
Neuropathy due  <bold> to </bold>drugs (HCC)  <bold> - </bold>Primary ICD-9-CM: 357.6 ICD-10-CM: G62.0 AMB REFERRAL TO PHYSICAL THERAPY [REF87 Custom] </text>
<text font_bg = '255,255,255'>
Tobacco abuse ICD-9-CM: 305.1 ICD-10-CM: Z72.0 AMB REFERRAL TO PHYSICAL THERAPY [REF87 Custom] </text>
<text font_bg = '255,255,255'>
Tobacco abuse counseling ICD-9-CM: V65.42, 305.1 ICD-10-CM: 271.6 AMB REFERRAL TO PHYSICAL THERAPY [REF87 Custom] </text>
<text font_bg = '255,255,255'>
Vasculopathy ICD-9-CM: 459.9 ICD-10-CM: 199.9 AMB REFERRAL TO PHYSICAL THERAPY [REF87 Custom] </text>
<text font_bg = '255,255,255'>
Dehydration ICD-9-CM: 276.51 ICD-10-CM: E86.0 AMB REFERRAL TO PHYSICAL THERAPY [REF87 Custom] </text>
<text font_bg = '255,255,255'>
Orthostatic hypotension ICD-9-CM: 458.0 ICD-10-CM: 195.1 AMB REFERRAL TO PHYSICAL THERAPY [REF87 Custom] </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 7 of 11 </text>
</page7>
<page8>
<text font_bg = '255,255,255'>
Neuralgia ICD-9-CM: 729.2 ICD-10-CM: M79.2 AMB REFERRAL TO PHYSICAL THERAPY [REF87 Custom] </text>
<text font_bg = '255,255,255'>
 <bold> Skin </bold>sensation disturbance ICD-9-CM: 782.0 ICD-10-CM: R20.9 AMB REFERRAL TO PHYSICAL THERAPY [REF87 Custom] </text>
<text font_bg = '255,255,255'>
Complete  <bold> below </bold> <bold> knee </bold>amputation  <bold> of </bold>right lower extremity,  <bold> initial </bold>encounter (HCC) </text>
<text font_bg = '255,255,255'>
ICD-9-CM: 897.0 ICD-10-CM: S88.111A AMB REFERRAL TO PHYSICAL THERAPY [REF87 Custom] </text>
<text font_bg = '255,255,255'>
 <bold> Gait </bold>abnormality ICD-9-CM: 781.2 ICD-10-CM: R26.9 AMB REFERRAL TO PHYSICAL THERAPY [REF87 Custom] </text>
<text font_bg = '255,255,255'>
Polyneuropathy  <bold> due </bold> <bold> to </bold>drug (HCC) ICD-9-CM: 357.6, E980.5 ICD-10-CM: G62.0 </text>
<text font_bg = '255,255,255'>
Allergies  <bold> as </bold> <bold> of </bold> <bold> 4/11/2016 </bold>No Known Allergies  <bold> Reviewed </bold>On: 4/11/2016 By:  <bold> Erica </bold> <bold> Newton </bold></text>
<text font_bg = '255,255,255'>
Outpatient  <bold> Medications </bold> <bold> as </bold> <bold> of </bold> <bold> 4/11/2016 </bold>Disp Refills amitriptyline (ELAVIL)  <bold> 25 </bold> <bold> mg </bold> <bold> tablet </bold>(Discontinued) Sig: Take 100 mg by mouth at bedtime daily. Class: Historical Med Route: Oral  <bold> ASCORBATE </bold> <bold> CALCIUM </bold>(VITAMIN  <bold> C </bold>PO) Sig: Take 500 mg by mouth. Class: Historical Med Route: Oral aspirin  <bold> EC </bold> <bold> 81 </bold> <bold> mg </bold>tablet Sig: Take 81 mg by mouth daily. Class: Historical Med Route: Oral buprenorphine  <bold> HCI </bold>(BELBUCA) 75  <bold> mcg </bold>film 60 Each  <bold> 0 </bold>(Taking/Discontinued) Sig: Place 75 mcg inside cheek (side of mouth) every 12 hours. Class: Print Route: Buccal carBAMazepine (TEGRETOL)  <bold> 200 </bold> <bold> mg </bold> <bold> tablet </bold>120 Tab  <bold> 5 </bold>Sig: Take  <bold> 1 </bold>Tab by mouth four times daily. Route: Oral cephalexin (KEFLEX)  <bold> 250 </bold> <bold> mg </bold>capsule 20 Cap  <bold> 0 </bold>Sig: One po qid Chromium Picolinate  <bold> 400 </bold> <bold> mcg </bold> <bold> tab </bold>Sig: Take by mouth daily. Metabolism/Heart Health Supplement Class: Historical Med Route: Oral coenzyme Q10(+)  <bold> 100 </bold> <bold> mg </bold> <bold> cap </bold>Sig: Take 100 mg by mouth. Class: Historical Med Start 4/11/2016 4/22/2015 7/28/2015 End 5/10/2016 5/10/2016 </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page  <bold> 8 </bold>of 11 </text>
<text font_bg = '255,255,255'>
Page  <bold> 8 </bold>of 11 </text>
<text font_bg = '255,255,255'>
Allergies  <bold> as </bold> <bold> of </bold> <bold> 4/11/2016 </bold> <bold> Reviewed </bold>On: 4/11/2016 By:  <bold> Erica </bold> <bold> Newton </bold></text>
<text>
Refills Start End </text>
<text>
 <bold> HCI </bold> <bold> mcg </bold>60 Each  <bold> 0 </bold>4/11/2016 5/10/2016 </text>
<text>
 <bold> 200 </bold> <bold> tablet </bold>120 Tab  <bold> 5 </bold>4/22/2015 </text>
<text>
 <bold> 250 </bold>20  <bold> 0 </bold>7/28/2015 </text>
<text font_bg = '244,250,255'>
Disp Refills  <bold> 25 </bold> <bold> tablet </bold>Start End 5/10/2016 </text>
<text>
 <bold> HCI </bold> <bold> mcg </bold>60 Each  <bold> 0 </bold>4/11/2016 5/10/2016 </text>
<text font_bg = '255,255,255'>
(MR # 1388862) Printed at 6/6/17 12:43 PM Page  <bold> 8 </bold>of 11 </text>
</page8>
<page9>
<text font_bg = '255,255,255'>
Route: Oral cyanocobalamin(+) (VITAMIN B-12)  <bold> 500 </bold> <bold> mcg </bold> <bold> tablet </bold>Sig: Take 500 mcg by mouth daily. Class: Historical Med Route: Oral diphenoxylate/atropine (LOMOTIL)  <bold> 2.5/0.025 </bold> <bold> mg </bold> <bold> tablet </bold>Sig: Take  <bold> 1 </bold>Tab by mouth four times daily  <bold> as </bold>needed. Class: Historical Med Route: Oral DULoxetine  <bold> DR </bold>(CYMBALTA)  <bold> 60 </bold> <bold> mg </bold>capsule (Discontinued) Sig: Take 60 mg by mouth daily. Class: Historical Med Route: Oral  <bold> EMOLLIENT </bold> <bold> BASE </bold>(VANICREAM TP) Sig: Apply to affected area. Class: Historical Med Route: Topical  <bold> FOLIC </bold> <bold> ACID/MULTIVITS-MIN </bold>(ADULT  <bold> MULTIVITAMIN </bold> <bold> GUMMIES </bold>PO) Sig: Take by mouth four times daily. Class: Historical Med Route: Oral  <bold> FOLIC </bold> <bold> ACID/MULTIVITS-MIN/LUT </bold>(CENTRUM  <bold> SILVER </bold>PO) Sig: Take by mouth. Class: Historical Med Route: Oral gabapentin (NEURONTIN)  <bold> 300 </bold> <bold> mg </bold>capsule 1080 Cap  <bold> 5 </bold>Sig: Take 3 tabs PO qid L.  <bold> ACIDOPHILUS/BIFID. </bold> <bold> ANIMALIS </bold>(CHEWABLE  <bold> PROBIOTIC </bold>PO) Sig: Take by mouth twice daily. 3am and 3 pm Class: Historical Med Route: Oral L.  <bold> RHAMNOSUS </bold> <bold> GG/INULIN </bold>(CULTURELLE  <bold> PROBIOTICS </bold>PO) Sig: Take by mouth. Class: Historical Med Route: Oral methadone (DOLOPHINE; METHADOSE)  <bold> 10 </bold> <bold> 90 </bold>Tab  <bold> 0 </bold> <bold> mg </bold> <bold> tablet </bold>(Discontinued) Sig: Take  <bold> 1 </bold>tab po three times  <bold> a </bold>day Class: Print other medication Sig: 120GM amitriptyline2%, Keta 5%, Lido 5%, Vanicream twice daily Class: Historical Med oxyCODONE (ROXICODONE) 5  <bold> mg </bold>tablet 60 Tab  <bold> 0 </bold>(Discontinued) Sig: Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed for Pain Class: Print Route: Oral Reason for Discontinue:  <bold> Reorder </bold>oxyCODONE-acetaminophen (PERCOCET; 120 Tab  <bold> 0 </bold>ENDOCET)  <bold> 10-325 </bold> <bold> mg </bold>tablet (Discontinued) 7/28/2015 7/28/2015 7/31/2015 9/21/2015 5/10/2016 4/11/2016 5/10/2016 5/10/2016 </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 9 of 11 </text>
<text>
 <bold> 300 </bold>1080  <bold> 5 </bold>7/28/2015 </text>
<text>
methadone  <bold> 10 </bold> <bold> 90 </bold>Tab  <bold> 0 </bold>7/28/2015 4/11/2016 </text>
<text>
 <bold> mg </bold>60 Tab  <bold> 0 </bold>7/31/2015 5/10/2016 </text>
<text>
120 Tab  <bold> 0 </bold>9/21/2015 5/10/2016 </text>
<text font_bg = '255,255,255'>
Page 9 of 11 </text>
<text>
DULoxetine  <bold> DR </bold> <bold> 60 </bold>5/10/2016 </text>
<text>
methadone  <bold> 10 </bold> <bold> 90 </bold>Tab  <bold> 0 </bold>7/28/2015 4/11/2016 </text>
<text>
 <bold> mg </bold>60 Tab  <bold> 0 </bold>7/31/2015 5/10/2016 </text>
<text>
120 Tab  <bold> 0 </bold>9/21/2015 5/10/2016 </text>
<text font_bg = '255,255,255'>
(MR # 1388862) Printed at 6/6/17 12:43 PM Page 9 of 11 </text>
</page9>
<page10>
<text font_bg = '255,255,255'>
Page 10 of 11 </text>
<text font_bg = '255,255,255'>
Sig: Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed Earliest Fill Date: 9/21/15 </text>
<text font_bg = '255,255,255'>
Class: Print Route: Oral Simethicone  <bold> 125 </bold> <bold> mg </bold> <bold> tab </bold>Sig: Take by mouth. Class: Historical  <bold> Med </bold>Route: Oral venlafaxine (EFFEXOR) 37.5  <bold> mg </bold>tablet (Discontinued) Sig: Take 37.5 mg by mouth twice daily. Class: Historical  <bold> Med </bold>Route: Oral Reason for Discontinue: Reorder 5/10/2016 </text>
<text font_bg = '255,255,255'>
Discontinued  <bold> Medications </bold></text>
<text>
venlafaxine 37.5  <bold> mg </bold>5/10/2016 </text>
<text font_bg = '255,242,240'>
Reason for Discontinue </text>
<text font_bg = '255,255,255'>
methadone (DOLOPHINE;  <bold> METHADOSE) </bold>10  <bold> mg </bold> <bold> tablet </bold></text>
<text font_bg = '255,255,255'>
Immunizations  <bold> as </bold>of 4/11/2016 No immunizations on file. Never Reviewed </text>
<text font_bg = '255,255,255'>
 <bold> KU </bold> <bold> REFERRING </bold> <bold> PROVIDER </bold>Referring Provider STOKES,  <bold> ROBERT </bold>[1111122] </text>
<text font_bg = '255,255,255'>
Level  <bold> of </bold>Service  <bold> PR </bold> <bold> OFFICE </bold>CONSULTATION,LEVEL  <bold> V </bold> <bold> [99245] </bold></text>
<text font_bg = '255,255,255'>
Immunizations  <bold> as </bold>of 4/11/2016 Never Reviewed </text>
<text font_bg = '255,255,255'>
Referring Provider STOKES,  <bold> ROBERT </bold>[1111122] </text>
<text font_bg = '0,112,193'>
Referring Provider </text>
<text font_bg = '255,255,255'>
 <bold> Robert </bold>Stokes,  <bold> MD </bold></text>
<text font_bg = '255,255,255'>
Routing History </text>
<text font_bg = '255,255,255'>
There  <bold> are </bold> <bold> no </bold>sent or routed communications associated with this encounter. </text>
<text font_bg = '255,255,255'>
Visit Information Provider  <bold> 4/11/2016 </bold> <bold> 9:45 </bold> <bold> AM </bold>Sherin Fetouh,  <bold> MD </bold>Clinic KUMED Dept CCC2 </text>
<text font_bg = '255,255,255'>
 <bold> All </bold>Flowsheet Templates (all recorded) Encounter Vitals Healthcare Providers Patient Room Number Vital Signs </text>
<text font_bg = '255,255,255'>
 <bold> BMI/ </bold> <bold> BSA </bold></text>
<text font_bg = '255,255,255'>
BMI: Body mass index is 21.38 kg/(m*2). </text>
<text font_bg = '255,255,255'>
BSA: Body surface  <bold> area </bold>is 1.95 meters squared. </text>
<table>
<tr>Charges

</tr>
<tr>Charge ID Procedure Code Qty. Modifiers

</tr>
<tr>78193858 HCCLC15100002 1

</tr>
<tr>78755266 99245 1


</tr>
</table>
<text font_bg = '255,255,255'>
Encounter Report Charge Ticket </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 10 of 11 </text>
<text font_bg = '255,255,255'>
 <bold> 4/11/2016 </bold> <bold> 9:45 </bold> <bold> AM </bold>Sherin Fetouh,  <bold> MD </bold>KUMED CCC2 </text>
<text font_bg = '244,250,255'>
Provider  <bold> 4/11/2016 </bold> <bold> 9:45 </bold> <bold> AM </bold>Sherin Fetouh,  <bold> MD </bold>Clinic KUMED Dept CCC2 </text>
<text font_bg = '244,250,255'>
Provider  <bold> 4/11/2016 </bold> <bold> 9:45 </bold> <bold> AM </bold>Sherin Fetouh,  <bold> MD </bold>Clinic KUMED Dept CCC2 </text>
<table>
<tr>Charge ID Procedure Code Qty. Modifiers

</tr>
<tr>78193858 HCCLC15100002 1

</tr>
<tr>78755266 99245 1


</tr>
</table>
<text font_bg = '255,255,255'>
(MR # 1388862) Printed at 6/6/17 12:43 PM Page 10 of 11 </text>
</page10>
<page11>
<text font_bg = '255,255,255'>
 <bold> Encounter </bold> <bold> Status </bold>Electronically Signed By Sherin Fetouh,  <bold> MD </bold> <bold> on </bold>4/21/16  <bold> at </bold>5:43  <bold> AM </bold></text>
<text font_bg = '255,255,255'>
Hospital  <bold> Account </bold>Name Acct  <bold> ID </bold>Class  <bold> 504899863 </bold>Cancer Series Status Closed </text>
<text font_bg = '255,255,255'>
 <bold> Account </bold> <bold> Information </bold></text>
<table>
<tr>Hospital Account Primary Payor Affiliated Recurring Accounts

</tr>
<tr>504899863 - BCBS KC 504899863

</tr>
<tr>[503200702]


</tr>
</table>
<text font_bg = '255,255,255'>
 <bold> Admission </bold>Diagnoses /  <bold> Reasons </bold>for  <bold> Visit </bold>(ICD-10-CM) </text>
<text font_bg = '255,255,255'>
Page 11 of 11 </text>
<text font_bg = '244,250,255'>
Name Acct  <bold> ID </bold>Class  <bold> 504899863 </bold>Cancer Series Status Closed </text>
<text font_bg = '255,255,255'>
Hospital Account Primary Payor Affiliated Recurring Accounts  <bold> 504899863 </bold> <bold> - </bold> <bold> BCBS </bold>KC  <bold> 504899863 </bold>Combined from HAR None </text>
<text font_bg = '244,250,255'>
Code Name Comments </text>
<text font_bg = '255,255,255'>
G62.0 Drug-induced polyneuropathy </text>
<text font_bg = '255,255,255'>
 <bold> Final </bold> <bold> Diagnoses </bold>(ICD-10-CM) </text>
<table>
<tr>Principal Code Name POA CC

</tr>
<tr>[P] G62.0 Drug-induced polyneuropathy


</tr>
<tr>272.0 Tobacco use


</tr>
<tr>271.6 Tobacco abuse counseling


</tr>
<tr>199.9 Unspecified disorder of circulatory system


</tr>
<tr>E86.0 Dehydration


</tr>
<tr>195.1 Orthostatic hypotension


</tr>
<tr>M79.2 Neuralgia and neuritis, unspecified


</tr>
<tr>R20.9 Unspecified disturbances of skin sensation


</tr>
</table>
<text font_bg = '255,255,255'>
$88.111A Complete traumatic amputation  <bold> at </bold>level between knee and ankle, right lower leg, initial encounter R26.9 Unspecified abnormalities of gait and mobility </text>
<text font_bg = '255,255,255'>
 <bold> CPT®/HCPCS </bold> <bold> Codes </bold></text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 11 of 11 </text>
<text font_bg = '244,250,255'>
Code Name POA CC Affects HAC DRG </text>
<text font_bg = '255,255,255'>
(MR # 1388862) Printed at 6/6/17 12:43 PM Page 11 of 11 </text>
</page11>
<page12>
<text>
 <bold> Office </bold> <bold> Visit </bold></text>
<text>
Page 1 of 11 </text>
<text>
 <bold> cct </bold> <bold> #: </bold> <bold> 4 </bold></text>
<text>
From Visit On: 05/10/16 </text>
<text>
 <bold> 5/10/2016 </bold> <bold> Pe </bold> <bold> | </bold> <bold> MRN: </bold> <bold> 1388862 </bold></text>
<text>
 <bold> Reason </bold>for Visit  <bold> Medication </bold>Follow-up Reason for Visit History </text>
<text>
 <bold> AVS </bold>Reports Date/Time Report 5/10/2016 12:00 After Visit Summary  <bold> PM </bold>Action Printed User Natasha Saunders </text>
<table>
<tr>Vital Signs

</tr>
<tr>BP Pulse Resp

</tr>
<tr>137/81 mmHg 92 12

</tr>
<tr>SpO2

</tr>
<tr>98%

</tr>
<tr>Vitals History


</tr>
</table>
<text>
Progress  <bold> Notes </bold>Melissa Smith,  <bold> RN </bold>at 05/10/16 1536 Status: Signed </text>
<text>
Date/Time Report 5/10/2016 12:00 After Visit Action Printed User Natasha Saunders </text>
<text>
BP Pulse Resp 137/81 mmHg  <bold> 92 </bold>12 Ht 182.9  <bold> cm </bold>(72") Wt  <bold> BMI </bold>92.08 kg (203 Ib) 27.53 </text>
<text>
Date/Time Report 5/10/2016 12:00 After Visit Action Printed User Natasha Saunders </text>
<text>
 <bold> Vital </bold>Signs  <bold> Most </bold>recent update: 5/10/2016 10:33  <bold> AM </bold>by D'Mesha Jefferson,  <bold> MA </bold></text>
<table>
<tr>BP Pulse Resp

</tr>
<tr>137/81 mmHg 92 12

</tr>
</table>
<text>
CVS pharmacy called  <bold> to </bold>state that Mr. Hunt picked up  <bold> a </bold>Nucynta 250mcg script yesterday from  <bold> a </bold>different provider. Discussed with Dr. Fetouh and he stated he  <bold> was </bold> <bold> aware </bold>and instructed that patient  <bold> not </bold>fill the 200mcg script. Called pharmacy and asked that they destroy the script. </text>
<text>
Sherin Fetouh,  <bold> MD </bold> <bold> at </bold>05/10/16 1029 Status: Signed </text>
<text>
Date of Service: 5/10/2016  <bold> Subjective: </bold> <bold> Past </bold> <bold> History: </bold></text>
<text>
He has chemotherapy induced polyneuropathy due  <bold> to </bold>oxalipatin and hand and foot syndrome due  <bold> to </bold>capecitabine.He received in addition epirubicin. He  <bold> was </bold>diagnosed with adenocarcinoma of  <bold> GE </bold>junction, T3N2 with removal of 30+ nodes and Roux  <bold> en </bold>Y surgery March 2013 Mayo Clinic. They diagnosed the hand  <bold> and </bold>foot syndrome and CIP neuropathy. He has been  <bold> a </bold>diabetic (type 2) for the past 10-15 years without any paresthesia. March 2013 he received chemotherapy, palms and soles began peeling, cracking of skin and developed ulcerations in both feet and  <bold> R </bold>hand. He underwent chemorx  <bold> 9 </bold>weeks. He developed buzzing  <bold> and </bold>tingling in the hands and dorsal feet after the hand and foot syndrome. He has noted numbness of last  <bold> 2 </bold>fingers of L hand in </text>
<text>
 <bold> PE </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 1 of 11 </text>
<text>
year. He feels  <bold> weak </bold>all  <bold> over </bold>but not focally. He is followed by  <bold> a </bold> <bold> wound </bold>specialist for 3 L foot ulcerations (required amputation March 2014 of the  <bold> 5th </bold>metatarsal) due  <bold> to </bold>osteomyelitis. He also has ulcerations under large  <bold> toe </bold> <bold> on </bold>L. He had  <bold> a </bold>deep ulceration palmar R index finger and several smaller  <bold> ones </bold>in both hands. He  <bold> uses </bold>hand lotion  <bold> bid </bold>and neuropathic topical  <bold> cream </bold>with amitryptiline. He  <bold> uses </bold> <bold> a </bold>scooter to relieve pressure  <bold> on </bold> <bold> feet </bold>for last year. Patient had  <bold> a </bold> <bold> BKA </bold>in September 2015, due  <bold> to </bold> <bold> an </bold>ankle fracture and subsequent infection. </text>
<text>
 <bold> History </bold> <bold> of </bold> <bold> Present </bold> <bold> Illness </bold> <bold> ACARI </bold>is  <bold> a </bold>57 y.o. male referred  <bold> to </bold> <bold> our </bold>clinic by Dr. Kiene for  <bold> severe </bold>CIPN, related  <bold> to </bold>gastric  <bold> cancer </bold>lagnosed  <bold> and </bold>treated in 2013 with Oxalaplatin. Patient has followed with Dr. April McVey in the Neurology department. Patient is  <bold> on </bold>Gabapentin 800mgQID, Cymbalta 60mg Daily, Nortriptyline 100mg QHS, Alpha Lipoic Acid 600mg  <bold> ER </bold>tablet daily, and is using  <bold> a </bold>compounding  <bold> cream </bold>with Amitriptyline 2%, Ketamine 5%, and </text>
<text>
Lidocaine 5%. He also takes Oxydocone 7.5/325 mg tablets, 4 tablets per day. He  <bold> was </bold>started  <bold> on </bold>Nucynta 250mg Q12H, prescribed by Dr. Kosa at NKCH Neurology Department. He  <bold> was </bold>transferred  <bold> to </bold>Meritas Pain </text>
<text>
(MR # 1388862) Printed at 6/6/17 12:43 PM Page 1 of 11 </text>
</page12>
<page13>
<text font_bg = '255,255,255'>
Page 2 of 11 </text>
<text font_bg = '255,255,255'>
Management with Dr. Gau, who  <bold> was </bold>transferred  <bold> to </bold> <bold> the </bold>Mayo Clinic. Dr. Dimachkie performed  <bold> EMG/NCS </bold>in January 2015 and found 1) moderate  <bold> to </bold> <bold> severe </bold>axonal neuropathy 2) bilateral ulnar neuropathies  <bold> at </bold> <bold> the </bold>elbows with conduction block  <bold> R </bold>elbow 3) active and chronic denervation in  <bold> R </bold>FDI, triceps and deltoid. </text>
<text font_bg = '255,255,255'>
 <bold> PAIN </bold> <bold> SURVEY </bold>Site: Feet,  <bold> Bil </bold>leg pain, Lower back, hands Onset (when did  <bold> it </bold>start): sept 2013 Timing (Intermittent  <bold> vs </bold>Constant)/ Duration  <bold> of </bold>episodic pain: constant Character (burning,aching, etc): sharp, stabbing, burning Radiation (does it travel down a limb): Up legs Alleviating Factors: medications Exacerbating Factors: Raising legs Severity (0-10): 2-10  <bold> He </bold>is here  <bold> today </bold>for follow-up and pain remains  <bold> not </bold>well controlled.  <bold> He </bold>has  <bold> failed </bold>Belbuca therapy. </text>
<text font_bg = '255,255,255'>
Review  <bold> of </bold>Systems </text>
<text font_bg = '255,255,255'>
Constitutional: Current everyday smoker.  <bold> HENT: </bold>Negative. Eyes: Negative. Respiratory: Negative. Cardiovascular: Negative. Gastrointestinal: Negative. Genitourinary: Negative. Musculoskeletal:  <bold> Left </bold> <bold> BKA </bold>due  <bold> to </bold> <bold> an </bold>ankle fracture.  <bold> Gait </bold>abnormality. Skin: Negative. Neurological: Severe CIPN. Hematological: Negative. Psychiatric/Behavioral: Negative. </text>
<text font_bg = '255,255,255'>
 <bold> Past </bold> <bold> Medical </bold>History Diagnosis Date  <bold> * </bold>Cancer (HCC)  <bold> ¢ </bold>Neuropathy  <bold> * </bold>Sleep disorder </text>
<text font_bg = '255,255,255'>
 <bold> Past </bold>Surgical History Procedure Laterality Date  <bold> ¢ </bold>Hx shoulder surgery Right  <bold> and </bold>left  <bold> ¢ </bold>Biceps tendon repair  <bold> ¢ </bold>Hx lumbar fusion  <bold> * </bold>Stomach surgery gastroectomy; roux-n-y  <bold> ¢ </bold>Prdebridement, skin, sub-q tissue,muscle,bone </text>
<table>
<tr>osteomyelitis

</tr>
<tr>Family History

</tr>
<tr>Problem Relation Age of Onset

</tr>
<tr>* Cancer Mother

</tr>
<tr>* Cancer Sister

</tr>
<tr>* Cancer Brother

</tr>
<tr>History

</tr>
<tr>Social History

</tr>
<tr>¢ Marital Status: Married

</tr>
<tr>Spouse Name: N/A

</tr>
<tr>¢ Number of Children: N/A


</tr>
</table>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 2 of 11 </text>
</page13>
<page14>
<text font_bg = '255,255,255'>
Years of Education:  <bold> N/A </bold></text>
<text font_bg = '238,238,238'>
Social History Main Topics </text>
<text>
Oth  <bold> er </bold>Concern </text>
<text font_bg = '255,255,255'>
Smoking status: Former Smoker </text>
<text>
Years of Education:  <bold> N/A </bold></text>
<text font_bg = '255,255,255'>
Page 3 of 11 </text>
<text font_bg = '255,255,255'>
status: Former Smoker </text>
<table>
<tr>Oth


</tr>
<tr>Quit date: 01/29/2009

</tr>
<tr>Smokeless tobacco: Not on file

</tr>
<tr>Alcohol Use: Not on file

</tr>
<tr>Drug Use: Not on file

</tr>
<tr>Sexual Activity: Not on file

</tr>
<tr>er Topics Concern

</tr>
<tr>None


</tr>
</table>
<text font_bg = '238,238,238'>
Social History Narrative </text>
<text>
 <bold> No </bold>Known </text>
<text font_bg = '255,255,255'>
 <bold> No </bold>Known Allergies </text>
<text>
 <bold> Objective: </bold></text>
<text font_bg = '255,255,255'>
ASCORBATE CALCIUM (VITAMIN C PO) aspirin  <bold> EC </bold> <bold> 81 </bold> <bold> mg </bold>tablet carBAMazepine (TEGRETOL)  <bold> 200 </bold> <bold> mg </bold>tablet cephalexin (KEFLEX)  <bold> 250 </bold>mg capsule Chromium Picolinate  <bold> 400 </bold>mcg  <bold> tab </bold>Take  <bold> 500 </bold>mg by mouth. Take  <bold> 81 </bold>mg by mouth daily. Take  <bold> 1 </bold>Tab by mouth four times daily. One po qid Take by mouth daily. Metabolism/Heart Health </text>
<text font_bg = '255,255,255'>
coenzyme Q10(+) 100 mg cap cyanocobalamin(+) (VITAMIN B-12)  <bold> 500 </bold>mcg tablet diphenoxylate/atropine (LOMOTIL) 2.5/0.025 mg tablet EMOLLIENT  <bold> BASE </bold>(VANICREAM TP) FOLIC ACID/MULTIVITS-MIN (ADULT MULTIVITAMIN  <bold> GUMMIES </bold>PO) FOLIC ACID/MULTIVITS-MIN/LUT (CENTRUM SILVER PO) gabapentin (NEURONTIN)  <bold> 300 </bold>mg capsule L. ACIDOPHILUS/BIFID. ANIMALIS (CHEWABLE PROBIOTIC PO) L.  <bold> RHAMNOSUS </bold>GG/INULIN (CULTURELLE PROBIOTICS PO) nortriptyline (PAMELOR)  <bold> 25 </bold>mg capsule other medication Take 100 mg by mouth. Take  <bold> 500 </bold>mcg by mouth daily. Take  <bold> 1 </bold>Tab by mouth four times daily  <bold> as </bold>needed. Apply  <bold> to </bold> <bold> affected </bold> <bold> area. </bold>Take by mouth four times daily. Take by mouth. Take  <bold> 3 </bold>tabs  <bold> PO </bold>qid Take by mouth twice daily. 3am and  <bold> 3 </bold>pm Take by mouth. Take  <bold> 1 </bold>Cap by mouth  <bold> at </bold>bedtime daily. 120GM  <bold> Keta </bold>5%, Lido 5%, </text>
<text font_bg = '255,255,255'>
oxyCODONE (ROXICODONE) 5  <bold> mg </bold>tablet Simethicone 125 mg  <bold> tab </bold>Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed for Pain Take by mouth. </text>
<text font_bg = '255,255,255'>
tapentadol (NUCYNTA ER)  <bold> 200 </bold>mg Tb12 venlafaxine (EFFEXOR) 37.5 mg tablet Take  <bold> 1 </bold>Tab by mouth every 12 hours Take  <bold> 1 </bold>Tab by mouth twice daily. </text>
<table>
<tr>Filed Vitals:


</tr>
<tr>05/10/16 1029

</tr>
<tr>BP: 137/81

</tr>
<tr>Pulse: 92

</tr>
<tr>Resp: 12

</tr>
<tr>Height: 182.9 cm (72")

</tr>
<tr>Weight: 92.08 kg (203 Ib)

</tr>
<tr>SpO2: 98%


</tr>
</table>
<text font_bg = '255,255,255'>
Body  <bold> mass </bold>index is 27.53 kg/(m‘2). </text>
<text font_bg = '255,255,255'>
Physical Exam </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 3 of 11 </text>
<text font_bg = '255,255,255'>
ASCORBATE CALCIUM (VITAMIN C PO) aspirin  <bold> EC </bold> <bold> 81 </bold> <bold> mg </bold>tablet carBAMazepine (TEGRETOL)  <bold> 200 </bold> <bold> mg </bold>tablet cephalexin (KEFLEX)  <bold> 250 </bold>mg capsule Chromium Picolinate  <bold> 400 </bold>mcg  <bold> tab </bold>coenzyme Q10(+) 100 mg cap cyanocobalamin(+) (VITAMIN B-12)  <bold> 500 </bold>mcg tablet diphenoxylate/atropine (LOMOTIL) 2.5/0.025 mg Take  <bold> 500 </bold>mg by mouth. Take  <bold> 81 </bold>mg by mouth daily. Take  <bold> 1 </bold>Tab by mouth four times daily. One po qid Take by mouth daily. Metabolism/Heart Health Supplement Take 100 mg by mouth. Take  <bold> 500 </bold>mcg by mouth daily. Take  <bold> 1 </bold>Tab by mouth four times daily  <bold> as </bold>needed. </text>
<text font_bg = '255,255,255'>
EMOLLIENT  <bold> BASE </bold>(VANICREAM TP) FOLIC ACID/MULTIVITS-MIN (ADULT Apply  <bold> to </bold> <bold> affected </bold> <bold> area. </bold>Take by mouth four times daily. </text>
<text font_bg = '255,255,255'>
FOLIC ACID/MULTIVITS-MIN/LUT (CENTRUM Take by mouth. </text>
<text font_bg = '255,255,255'>
gabapentin (NEURONTIN)  <bold> 300 </bold>mg capsule L. ACIDOPHILUS/BIFID. ANIMALIS (CHEWABLE Take  <bold> 3 </bold>tabs  <bold> PO </bold>qid Take by mouth twice daily. 3am and  <bold> 3 </bold>pm </text>
<text font_bg = '255,255,255'>
L.  <bold> RHAMNOSUS </bold>GG/INULIN (CULTURELLE Take by mouth. </text>
<text font_bg = '255,255,255'>
nortriptyline (PAMELOR)  <bold> 25 </bold>mg capsule other medication oxyCODONE (ROXICODONE) 5  <bold> mg </bold>tablet Simethicone 125 mg  <bold> tab </bold>tapentadol (NUCYNTA ER)  <bold> 200 </bold>mg Tb12 venlafaxine (EFFEXOR) 37.5 mg tablet Take  <bold> 1 </bold>Cap by mouth  <bold> at </bold>bedtime daily. 120GM amitriptyline2%,  <bold> Keta </bold>5%, Lido 5%, Vanicream twice daily Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed for Pain Take by mouth. Take  <bold> 1 </bold>Tab by mouth every 12 hours Take  <bold> 1 </bold>Tab by mouth twice daily. </text>
<text font_bg = '255,255,255'>
(MR # 1388862) Printed at 6/6/17 12:43 PM Page 3 of 11 </text>
</page14>
<page15>
<text font_bg = '255,255,255'>
Page 4 of 11 </text>
<text font_bg = '255,255,255'>
Ortho Exam </text>
<text font_bg = '255,255,255'>
 <bold> Physical </bold> <bold> Exam </bold>Constitutional: appears well-developed.  <bold> No </bold>distress. </text>
<text font_bg = '255,255,255'>
Head: Normocephalic and atraumatic. Eyes: Conjunctivae  <bold> are </bold>normal.  <bold> No </bold>scleral icterus. Neck: Normal range of motion. Neck supple. Cardiovascular: Normal rate and regular rhythm. Pulmonary/Chest:  <bold> Effort </bold>normal.  <bold> No </bold>respiratory distress. Abdominal: Soft. There is  <bold> no </bold>tenderness. Skin: Skin is  <bold> warm </bold>and dry. MSK: Atrophy of the  <bold> left </bold>calf muscle, intrinsic hand muscle wasting. Left 5th toes amputated, with significant abnormality of the  <bold> left </bold>later foot,  <bold> at </bold>the arch. Well-healed right  <bold> BKA </bold>residual limb, with  <bold> a </bold>very small, scabbed  <bold> wound </bold>the size of  <bold> a </bold>pin point. 10-ply socks removed from the residual limb. Neuro: CNII-XII grossly intact. AxOx3. Sensation  <bold> to </bold>light touch diminished in  <bold> a </bold>stocking-glove distribution, in the BUE/BLE. Impaired gait with  <bold> R </bold> <bold> BKA </bold>prosthetic, with  <bold> a </bold>SPC. Proprioception intact at the b/l ankles, and impaired  <bold> at </bold>the b/I great toes. Psychiatric: normal mood  <bold> and </bold>affect. Behavior is normal. </text>
<text font_bg = '255,255,255'>
 <bold> GEE </bold> <bold> «was </bold> <bold> seen </bold>today for medication follow-up. </text>
<text font_bg = '255,255,255'>
Diagnoses and all orders for this visit: </text>
<text font_bg = '255,255,255'>
 <bold> Phantom </bold> <bold> limb </bold>pain (HCC) Orders:  <bold> - </bold>oxyCODONE (ROXICODONE)  <bold> 5 </bold> <bold> mg </bold>tablet; Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed for Pain  <bold> - </bold>tapentadol (NUCYNTA ER) 200 mg Tb12; Take  <bold> 1 </bold>Tab by mouth every 12 hours  <bold> - </bold>nortriptyline (PAMELOR) 25 mg capsule; Take  <bold> 1 </bold>Cap by mouth at bedtime daily. </text>
<text font_bg = '255,255,255'>
 <bold> Chronic </bold>pain syndrome Orders:  <bold> - </bold>oxyCODONE (ROXICODONE)  <bold> 5 </bold> <bold> mg </bold>tablet; Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed for Pain  <bold> - </bold>tapentadol (NUCYNTA ER) 200 mg Tb12; Take  <bold> 1 </bold>Tab by mouth every 12 hours  <bold> - </bold>nortriptyline (PAMELOR) 25 mg capsule; Take  <bold> 1 </bold>Cap by mouth at bedtime daily. </text>
<text font_bg = '255,255,255'>
Chemotherapy-induced peripheral neuropathy (HCC) Orders:  <bold> - </bold>venlafaxine (EFFEXOR) 37.5 mg tablet; Take  <bold> 1 </bold>Tab by mouth twice daily.  <bold> - </bold>oxyCODONE (ROXICODONE)  <bold> 5 </bold> <bold> mg </bold>tablet; Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed for Pain  <bold> - </bold>tapentadol (NUCYNTA ER) 200 mg Tb12; Take  <bold> 1 </bold>Tab by mouth every 12 hours  <bold> - </bold>nortriptyline (PAMELOR) 25 mg capsule; Take  <bold> 1 </bold>Cap by mouth at bedtime daily. </text>
<text font_bg = '255,255,255'>
Neuralgia Orders:  <bold> - </bold>oxyCODONE (ROXICODONE)  <bold> 5 </bold> <bold> mg </bold>tablet; Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed for Pain  <bold> - </bold>tapentadol (NUCYNTA ER) 200 mg Tb12; Take  <bold> 1 </bold>Tab by mouth every 12 hours  <bold> - </bold>nortriptyline (PAMELOR) 25 mg capsule; Take  <bold> 1 </bold>Cap by mouth at bedtime daily. </text>
<text font_bg = '255,255,255'>
Chronic, continuous  <bold> use </bold> <bold> of </bold>opioids Orders:  <bold> - </bold>oxyCODONE (ROXICODONE)  <bold> 5 </bold> <bold> mg </bold>tablet; Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed for Pain  <bold> - </bold>tapentadol (NUCYNTA ER) 200 mg Tb12; Take  <bold> 1 </bold>Tab by mouth every 12 hours  <bold> - </bold>nortriptyline (PAMELOR) 25 mg capsule; Take  <bold> 1 </bold>Cap by mouth at bedtime daily. </text>
<text font_bg = '255,255,255'>
 <bold> Assessment </bold> <bold> and </bold> <bold> Plan: </bold>Patient is  <bold> a </bold>pleasant 57 yo male with  <bold> a </bold>history of gastric  <bold> cancer </bold>diagnosed and treated in 2013 with Oxaloplatin, </text>
<text font_bg = '255,255,255'>
who developed  <bold> severe </bold>CIPN. Patient also with  <bold> a </bold>history of  <bold> DM </bold>type II and  <bold> was </bold> <bold> a </bold>former smoker.  <bold> H&P </bold>is consistent with: </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 4 of 11 </text>
</page15>
<page16>
<text font_bg = '255,255,255'>
Page 5 of 11 </text>
<text font_bg = '255,255,255'>
CIPN,  <bold> severe </bold> <bold> . </bold>High fall risk  <bold> . </bold>Impaired gait and balance  <bold> . </bold>Neuropathic pain  <bold> . </bold>Prior history of  <bold> DM </bold>type  <bold> 2 </bold>Tobaccoism  <bold> R </bold> <bold> BKA </bold> <bold> . </bold>Left foot deformity ONDONRWON= </text>
<text>
CIPN,  <bold> severe </bold> <bold> . </bold>High fall risk  <bold> . </bold>Impaired gait and balance  <bold> . </bold>Neuropathic pain  <bold> . </bold>Prior history of  <bold> DM </bold>type  <bold> 2 </bold>Tobaccoism  <bold> R </bold> <bold> BKA </bold> <bold> . </bold>Left foot ONDONRWON= </text>
<text font_bg = '255,255,255'>
PLAN: 1. Lifestyle: Patient provided  <bold> a </bold>home safety checklist, to help reduce his fall risk. Patient to  <bold> use </bold> <bold> a </bold> <bold> SPC </bold>at all time. Patient  <bold> was </bold>counseled regarding smoking cessation. Patient  <bold> was </bold>refitted for  <bold> a </bold> <bold> new </bold>prosthetic at the Leavenworth VA, through Horizons at NKCH. Dr. Kiene at the Leavenworth VA will follow up  <bold> on </bold>the script. Patient also provided contact information for  <bold> a </bold>Podiatrist, Stephanie Jameson, at KC Foot and Ankle. Patient may also contact Dr. Fines,  <bold> a </bold>Podiatrist, at NKCH. 2. Medications: Patient will continue the Gabapentin 800mg QID, Cymbalta 60mg Daily, Alpha Lipoic Acid 600mg  <bold> ER </bold>Daily, Oxycodone 7.5-325mg  <bold> Q6H </bold>prn,  <bold> max </bold>4 tabs per day, Nortriptyline 50mg QHS, and compounding cream. We had him trial Belbuca (buprenorphine) film to the inside of the cheek, Q12H. He  <bold> was </bold>non-compliant with  <bold> use </bold>We will have him restart nucynta  <bold> as </bold>above. 3. Therapy: Prescribed PT for impaired gait, balance, and  <bold> new </bold>prosthetic training. Also, will evaluate for DME.  <bold> New </bold>script provided today for NKCH. 4. Diagnostics:  <bold> EDX </bold>completed by Dr. Dimachke in January 2015, showing  <bold> severe </bold>axonal peripheral neuropathy. 5. Interventions:  <bold> Not </bold>indicated at this time. 6. Follow up in 4 weeks. </text>
<text font_bg = '255,255,255'>
 <bold> Staff </bold> <bold> name: </bold>Sherin Fetouh,  <bold> MD </bold>5/22/2016 </text>
<text font_bg = '255,255,255'>
Revision History ©) </text>
<text font_bg = '255,255,255'>
 <bold> Goals </bold> <bold> (2 </bold> <bold> Years </bold> <bold> of </bold> <bold> Data) </bold> <bold> as </bold> <bold> of </bold> <bold> 5/10/16 </bold></text>
<table>
<tr>None

</tr>
<tr>Reviewed: 5/22/2016 12:25 PM by Sherin

</tr>
<tr>Problem List Fetouh, MD

</tr>
<tr>Priority Class Noted Last Modified

</tr>
<tr>Hand and foot syndrome after chemotherapy 2/6/2015 2/6/2015 by

</tr>
<tr>April McVey

</tr>
<tr>Neuropathy due to oxaliplatin 2/6/2015 2/6/2015 by

</tr>
<tr>April McVey

</tr>
<tr>Bilateral ulnar neruopathies 2/6/2015 2/6/2015 by

</tr>
<tr>April McVey

</tr>
<tr>Medical Past Medical History Date Comments Source

</tr>
<tr>as of 5/10/2016 Cancer (HCC) [C80.1] Provider

</tr>
<tr>Neuropathy [G62.9] Provider


</tr>
</table>
<text font_bg = '255,255,255'>
 <bold> PE </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 5 of 11 </text>
</page16>
<page17>
<text font_bg = '255,255,255'>
Page 6 of 11 </text>
<table>
<tr>Sleep disorder [G47.9] Provider

</tr>
<tr>Surgical Past Surgical History Laterality Date Comments Source

</tr>
<tr>as of HX SHOULDER SURGERY [HX334] Right and left Provider

</tr>
<tr>5/10/2016

</tr>
<tr>BICEPS TENDON REPAIR [SHX566] Provider

</tr>
<tr>HX LUMBAR FUSION [SHX111] Provider

</tr>
<tr>STOMACH SURGERY [SHX791] gastroectomy; Provider

</tr>
<tr>roux-n-y

</tr>
<tr>PR DEBRIDEMENT BONE MUSCLE osteomyelitis Provider

</tr>
<tr>&/FASCIA 20 SQ CM/< [11044]

</tr>
<tr>Family Problem Relation Name Age of Onset Comments Source

</tr>
<tr>as of 5/10/2016 Cancer Mother Provider

</tr>
<tr>Cancer Sister Provider

</tr>
<tr>Cancer Brother Provider


</tr>
</table>
<text font_bg = '255,255,255'>
Family  <bold> Status </bold>**None** </text>
<table>
<tr>as of 5/10/2016

</tr>
<tr>Tobacco Use Smoking Source Types Packs/day Years Comments Smoking Smoking Smokeless Smokeless

</tr>
<tr>Status Used Start Quit Date Tobacco Tobacco

</tr>
<tr>Date Status Quit Date


</tr>
<tr>as of Former Provider 0.0 0.0 1/29/2009 Unknown


</tr>
<tr>5/10/2016 Smoker

</tr>
<tr>Alcohol Use Alcohol Use Source Drinks/Week Alcohol/(Wk Comments


</tr>
<tr>as of 5/10/2016 Not Asked Provider


</tr>
<tr>Drug Use Drug Use Source Types Frequency Comments


</tr>
<tr>as of 5/10/2016 Not Asked Provider 0.00


</tr>
<tr>Sexual Activity Sexually Active Source Birth Control Partners Comments


</tr>
<tr>as of 5/10/2016 Not Asked Provider


</tr>
<tr>Social ADL ADL Question Response Comments Source

</tr>
<tr>as of 5/10/2016 **None**


</tr>
<tr>Social Doc **None**


</tr>
<tr>as of 5/10/2016


</tr>
<tr>Occupational **None**


</tr>
<tr>as of 5/10/2016


</tr>
<tr>Socioeconomic Marital Status Spouse Name Num of Children Years Education Source

</tr>
<tr>as of 5/10/2016 Married


</tr>
<tr>Preferred Ethnicity Race

</tr>
<tr>Language


</tr>
</table>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 6 of 11 </text>
</page17>
<page18>
<text font_bg = '255,255,255'>
Page 7 of 11 </text>
<text font_bg = '237,237,237'>
ENGLISH Non Hispanic, Latino or White or Caucasian Spanish Origin </text>
<table>
<tr>Birth **None**


</tr>
<tr>Advance Q A Comments


</tr>
<tr>Directives


</tr>
<tr>Status


</tr>
<tr>as of 5/10/2016 Do You Have Living Will Or No No on 4/11/2016

</tr>
<tr>Advance Directive?


</tr>
<tr>Past Q A Comments


</tr>
</table>
<text font_bg = '255,255,255'>
 <bold> Hospitalizations </bold> <bold> 7 </bold> <bold> as </bold> <bold> of </bold> <bold> 5/10/2016 </bold>Past Hospitalizations? </text>
<text font_bg = '255,255,255'>
 <bold> Additional </bold>History </text>
<text font_bg = '255,255,255'>
History Last reviewed in  <bold> this </bold>visit by  <bold> D'Mesha </bold>Jefferson,  <bold> MA </bold> <bold> on </bold> <bold> 5/10/2016 </bold> <bold> at </bold>10:34  <bold> AM </bold></text>
<text font_bg = '255,255,255'>
Sections Reviewed Custom, Medical, Surgical, Tobacco, Alcohol, Drug Use, Sexual Activity, ADL, Socioeconomic, Family </text>
<text font_bg = '255,255,255'>
History Last  <bold> Reviewed </bold>by  <bold> D'Mesha </bold>Jefferson,  <bold> MA </bold> <bold> on </bold> <bold> 5/10/2016 </bold> <bold> at </bold>10:34  <bold> AM </bold></text>
<text font_bg = '255,255,255'>
Tobacco  <bold> use </bold></text>
<text font_bg = '255,255,255'>
Last reviewed 5/10/2016 </text>
<text font_bg = '255,255,255'>
 <bold> Visit </bold>Diagnoses  <bold> and </bold>Associated Orders  <bold> Phantom </bold> <bold> limb </bold>pain (HCC)  <bold> - </bold>Primary ICD-9-CM: 353.6 ICD-10-CM: G54.7 oxyCODONE (ROXICODONE)  <bold> 5 </bold> <bold> mg </bold>tablet [10814] tapentadol (NUCYNTA ER) 200 mg Tb12 [308550] nortriptyline (PAMELOR) 25 mg capsule [5675] </text>
<text font_bg = '255,255,255'>
Chronic pain syndrome ICD-9-CM: 338.4 ICD-10-CM: G89.4 oxyCODONE (ROXICODONE) 5  <bold> mg </bold>tablet [10814] tapentadol (NUCYNTA ER) 200 mg Tb12 [308550] nortriptyline (PAMELOR) 25 mg capsule [5675] </text>
<text font_bg = '255,255,255'>
Chemotherapy-induced peripheral neuropathy (HCC) ICD-9-CM: 357.7, E933.1 ICD-10-CM: G62.0, T45.1X5A venlafaxine (EFFEXOR) 37.5 mg tablet [80444] oxyCODONE (ROXICODONE) 5  <bold> mg </bold>tablet [10814] tapentadol (NUCYNTA ER) 200 mg Tb12 [308550] nortriptyline (PAMELOR) 25 mg capsule [5675] </text>
<text font_bg = '255,255,255'>
Neuralgia ICD-9-CM: 729.2 ICD-10-CM: M79.2 oxyCODONE (ROXICODONE) 5  <bold> mg </bold>tablet [10814] tapentadol (NUCYNTA ER) 200 mg Tb12 [308550] </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 7 of 11 </text>
</page18>
<page19>
<text font_bg = '255,255,255'>
nortriptyline (PAMELOR) 25 mg capsule [5675] </text>
<text font_bg = '255,255,255'>
Chronic, continuous  <bold> use </bold>of opioids ICD-9-CM: 305.51 ICD-10-CM: F11.90 oxyCODONE (ROXICODONE)  <bold> 5 </bold> <bold> mg </bold>tablet [10814] tapentadol (NUCYNTA ER) 200 mg Tb12 [308550] nortriptyline (PAMELOR) 25 mg capsule [5675] </text>
<text font_bg = '255,255,255'>
Follow-up  <bold> and </bold>Disposition Return in about 4 weeks (around 6/7/2016). Follow-up and Disposition History </text>
<text font_bg = '255,255,255'>
Page  <bold> 8 </bold>of 11 </text>
<text font_bg = '255,255,255'>
 <bold> Reviewed </bold>On:  <bold> 5/10/2016 </bold>By:  <bold> D'Mesha </bold></text>
<text font_bg = '255,255,255'>
Allergies  <bold> as </bold> <bold> of </bold> <bold> 5/10/2016 </bold>No Known Allergies Jefferson,  <bold> MA </bold></text>
<text font_bg = '255,255,255'>
Allergies  <bold> as </bold> <bold> of </bold> <bold> 5/10/2016 </bold>Jefferson,  <bold> MA </bold></text>
<text font_bg = '255,255,255'>
Outpatient  <bold> Medications </bold> <bold> as </bold> <bold> of </bold> <bold> 5/10/2016 </bold></text>
<text font_bg = '255,255,255'>
Disp Refills Start amitriptyline (ELAVIL)  <bold> 25 </bold> <bold> mg </bold> <bold> tablet </bold>(Discontinued) Sig: Take 100 mg by mouth at bedtime daily. Class: Historical Med Route: Oral  <bold> ASCORBATE </bold> <bold> CALCIUM </bold>(VITAMIN  <bold> C </bold>PO) (Taking) Sig: Take 500 mg by mouth. Class: Historical Med Route: Oral aspirin  <bold> EC </bold> <bold> 81 </bold> <bold> mg </bold> <bold> tablet </bold>(Taking) Sig: Take 81 mg by mouth daily. Class: Historical Med Route: Oral End 5/10/2016 </text>
<text font_bg = '255,255,255'>
buprenorphine  <bold> HCI </bold>(BELBUCA)  <bold> 75 </bold> <bold> mcg </bold>film 60 Each  <bold> 0 </bold>4/11/2016 5/10/2016 </text>
<text font_bg = '255,255,255'>
(Discontinued) Sig: Place 75 mcg inside cheek (side of mouth) every 12 hours. Class: Print Route: Buccal </text>
<text font_bg = '255,255,255'>
carBAMazepine (TEGRETOL)  <bold> 200 </bold> <bold> mg </bold> <bold> tablet </bold>120 Tab  <bold> 5 </bold>4/22/2015 </text>
<text font_bg = '255,255,255'>
(Taking) Sig: Take  <bold> 1 </bold>Tab by mouth four times daily. Route: Oral </text>
<text font_bg = '255,255,255'>
cephalexin (KEFLEX)  <bold> 250 </bold> <bold> mg </bold>capsule 20 Cap  <bold> 0 </bold>7/28/2015 </text>
<text font_bg = '255,255,255'>
(Taking) Sig: One po qid Chromium Picolinate  <bold> 400 </bold> <bold> mcg </bold> <bold> tab </bold>(Taking) Sig: Take by mouth daily. Metabolism/Heart Health Supplement Class: Historical Med Route: Oral coenzyme Q10(+)  <bold> 100 </bold> <bold> mg </bold> <bold> cap </bold>(Taking) Sig: Take 100 mg by mouth. Class: Historical Med Route: Oral cyanocobalamin(+) (VITAMIN B-12)  <bold> 500 </bold> <bold> mcg </bold> <bold> tablet </bold>Sig: Take 500 mcg by mouth daily. Class: Historical Med Route: Oral </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page  <bold> 8 </bold>of 11 </text>
<text font_bg = '244,250,255'>
Disp Refills Start  <bold> 25 </bold> <bold> tablet </bold>End 5/10/2016 </text>
<text>
 <bold> HCI </bold> <bold> 75 </bold> <bold> mcg </bold>60 Each  <bold> 0 </bold>4/11/2016 5/10/2016 </text>
<text font_bg = '255,255,255'>
(MR # 1388862) Printed at 6/6/17 12:43 PM Page  <bold> 8 </bold>of 11 </text>
</page19>
<page20>
<text font_bg = '255,255,255'>
diphenoxylate/atropine (LOMOTIL)  <bold> 2.5/0.025 </bold> <bold> mg </bold> <bold> tablet </bold>(Taking) Sig: Take  <bold> 1 </bold>Tab by mouth four times daily  <bold> as </bold>needed. Class: Historical Med Route: Oral DULoxetine  <bold> DR </bold>(CYMBALTA)  <bold> 60 </bold> <bold> mg </bold>capsule (Discontinued) Sig: Take 60 mg by mouth daily. Class: Historical Med Route: Oral  <bold> EMOLLIENT </bold> <bold> BASE </bold>(VANICREAM TP) (Taking) Sig: Apply to affected area. Class: Historical Med Route: Topical  <bold> FOLIC </bold> <bold> ACID/MULTIVITS-MIN </bold>(ADULT  <bold> MULTIVITAMIN </bold> <bold> GUMMIES </bold>PO) (Taking) Sig: Take by mouth four times daily. Class: Historical Med Route: Oral  <bold> FOLIC </bold> <bold> ACID/MULTIVITS-MIN/LUT </bold>(CENTRUM  <bold> SILVER </bold>PO) (Taking) Sig: Take by mouth. Class: Historical Med Route: Oral gabapentin (NEURONTIN)  <bold> 300 </bold> <bold> mg </bold>capsule 1080 Cap  <bold> 5 </bold>(Taking) Sig: Take 3 tabs PO qid L.  <bold> ACIDOPHILUS/BIFID. </bold> <bold> ANIMALIS </bold>(CHEWABLE  <bold> PROBIOTIC </bold>PO) (Taking) Sig: Take by mouth twice daily. 3am and 3 pm Class: Historical Med Route: Oral L.  <bold> RHAMNOSUS </bold> <bold> GG/INULIN </bold>(CULTURELLE  <bold> PROBIOTICS </bold>PO) (Taking) Sig: Take by mouth. Class: Historical Med Route: Oral nortriptyline (PAMELOR)  <bold> 25 </bold> <bold> mg </bold>capsule  <bold> 90 </bold>Cap  <bold> 1 </bold>(Taking) Sig: Take  <bold> 1 </bold>Cap by mouth at bedtime daily. Route: Oral other medication (Taking) Sig: 120GM amitriptyline2%, Keta 5%, Lido 5%, Vanicream twice daily Class: Historical Med 7/28/2015 5/10/2016 5/10/2016 </text>
<table>
<tr>oxyCODONE (ROXICODONE) 5 mg tablet 120 Tab 0

</tr>
<tr>(Taking)

</tr>
<tr>Sig: Take 1 Tab by mouth every 6 hours as needed for Pain

</tr>
<tr>Class: Print

</tr>
<tr>Route: Oral

</tr>
<tr>oxyCODONE (ROXICODONE) 5 mg tablet 60 Tab 0


</tr>
</table>
<text font_bg = '255,255,255'>
(Discontinued) Sig: Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed for Pain Class: Print Route: Oral Reason for Discontinue:  <bold> Reorder </bold>oxyCODONE-acetaminophen (PERCOCET; 120 Tab  <bold> 0 </bold>ENDOCET)  <bold> 10-325 </bold> <bold> mg </bold>tablet (Discontinued) 9/21/2015 5/10/2016 </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 9 of 11 </text>
<text>
 <bold> 300 </bold>1080  <bold> 5 </bold>7/28/2015 </text>
<text>
 <bold> 25 </bold> <bold> 90 </bold> <bold> 1 </bold>5/10/2016 </text>
<text>
 <bold> mg </bold>120 Tab  <bold> 0 </bold>5/10/2016 </text>
<text>
 <bold> mg </bold>60 Tab  <bold> 0 </bold>7/31/2015 5/10/2016 </text>
<text>
120 Tab  <bold> 0 </bold>9/21/2015 5/10/2016 </text>
<text font_bg = '255,255,255'>
Page 9 of 11 </text>
<text>
DULoxetine  <bold> DR </bold> <bold> 60 </bold>5/10/2016 </text>
<text>
 <bold> mg </bold>60 Tab  <bold> 0 </bold>7/31/2015 5/10/2016 </text>
<text>
120 Tab  <bold> 0 </bold>9/21/2015 5/10/2016 </text>
<text font_bg = '255,255,255'>
(MR # 1388862) Printed at 6/6/17 12:43 PM Page 9 of 11 </text>
</page20>
<page21>
<text font_bg = '255,255,255'>
Sig: Take  <bold> 1 </bold>Tab by mouth every  <bold> 6 </bold>hours  <bold> as </bold>needed Earliest Fill Date: 9/21/15 Class: Print Route: Oral oxyCODONE-acetaminophen(+) 4/19/2016 (PERCOCET;  <bold> ENDOCET) </bold>7.5-325  <bold> mg </bold> <bold> tablet </bold>(Discontinued) Sig:  <bold> 1 </bold>Tab every 4 hours Class: Historical Med Simethicone  <bold> 125 </bold> <bold> mg </bold> <bold> tab </bold>(Taking) Sig: Take by mouth. Class: Historical Med Route: Oral tapentadol (NUCYNTA  <bold> ER) </bold> <bold> 200 </bold> <bold> mg </bold>Tb12 60 Tab  <bold> 0 </bold>5/10/2016 (Taking) Sig: Take  <bold> 1 </bold>Tab by mouth every 12 hours Class: Print Route: Oral venlafaxine (EFFEXOR) 37.5  <bold> mg </bold>tablet 180 Tab  <bold> 1 </bold>5/10/2016 (Taking) Sig: Take  <bold> 1 </bold>Tab by mouth twice daily. Route: Oral venlafaxine (EFFEXOR) 37.5  <bold> mg </bold>tablet (Discontinued) Sig: Take 37.5 mg by mouth twice daily. Class: Historical Med Route: Oral Reason for Discontinue: Reorder 5/10/2016 5/10/2016 </text>
<text font_bg = '255,255,255'>
Discontinued Medications Reason for Discontinue buprenorphine  <bold> HCI </bold>(BELBUCA) 75  <bold> mcg </bold>film oxyCODONE-acetaminophen (PERCOCET; ENDOCET) 10-325  <bold> mg </bold>tablet oxyCODONE-acetaminophen(+) (PERCOCET; ENDOCET) 7.5-325  <bold> mg </bold> <bold> tablet </bold>DULoxetine  <bold> DR </bold>(CYMBALTA)  <bold> 60 </bold> <bold> mg </bold>capsule amitriptyline (ELAVIL)  <bold> 25 </bold> <bold> mg </bold> <bold> tablet </bold></text>
<text font_bg = '255,255,255'>
 <bold> Medication </bold> <bold> Notes </bold>oxyCODONE-acetaminophen(+) (PERCOCET;  <bold> ENDOCET) </bold>7.5-325  <bold> mg </bold>tablet D'Mesha Jefferson, MA 5/10/2016 10:34 AM Received Sig: </text>
<text font_bg = '255,255,255'>
Immunizations  <bold> as </bold>of  <bold> 5/10/2016 </bold>No immunizations on file. Never Reviewed </text>
<text font_bg = '255,255,255'>
 <bold> KU </bold> <bold> REFERRING </bold> <bold> PROVIDER </bold></text>
<text font_bg = '255,255,255'>
Level of Service  <bold> PR </bold> <bold> OFFICE/OUTPT </bold>VISIT,EST,LEVL  <bold> IV </bold>[99214] </text>
<text font_bg = '255,255,255'>
Routing History There are no sent or routed communications associated with this encounter. </text>
<text font_bg = '244,250,255'>
Visit Information Provider Clinic  <bold> 5/10/2016 </bold> <bold> 10:00 </bold> <bold> AM </bold>Sherin Fetouh, MD KUMED Dept INSPRHBMED </text>
<text font_bg = '255,255,255'>
 <bold> All </bold>Flowsheet Templates (all recorded) </text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 10 of 11 </text>
<text font_bg = '255,255,255'>
Page 10 of 11 </text>
<text>
4/19/2016 5/10/2016 </text>
<text>
venlafaxine 37.5  <bold> mg </bold>5/10/2016 </text>
<text font_bg = '255,255,255'>
Immunizations  <bold> as </bold>of  <bold> 5/10/2016 </bold>Never Reviewed </text>
<text font_bg = '244,250,255'>
Provider Clinic  <bold> 5/10/2016 </bold> <bold> 10:00 </bold> <bold> AM </bold>Sherin Fetouh, MD KUMED Dept INSPRHBMED </text>
<text font_bg = '255,255,255'>
(MR # 1388862) Printed at 6/6/17 12:43 PM Page 10 of 11 </text>
</page21>
<page22>
<text font_bg = '255,255,255'>
Page 11 of 11 </text>
<text font_bg = '255,255,255'>
Encounter Vitals Healthcare Providers Oswestry Questionnaire </text>
<text font_bg = '255,255,255'>
 <bold> BMI/ </bold> <bold> BSA </bold></text>
<text font_bg = '255,255,255'>
 <bold> BMI: </bold>Body  <bold> mass </bold>index is 27.53 kg/(m*2). </text>
<text font_bg = '255,255,255'>
 <bold> BSA: </bold> <bold> Body </bold>surface  <bold> area </bold> <bold> is </bold>2.16 meters squared. </text>
<table>
<tr>Charges

</tr>
<tr>Charge ID Procedure Code Qty. Modifiers Diagnosis Encounter Provider Status

</tr>
<tr>80459266 99214 1 G54.7 Sherin Fetouh, MD Filed

</tr>
<tr>80648403 HCCLC25100009 1 G54.7 D'Mesha Jefferson, MA Filed


</tr>
</table>
<text font_bg = '255,255,255'>
 <bold> Encounter </bold>Report Charge Ticket </text>
<text font_bg = '255,255,255'>
 <bold> Encounter </bold> <bold> Status </bold>Electronically Signed By Sherin Fetouh,  <bold> MD </bold> <bold> on </bold>5/22/16  <bold> at </bold>12:25  <bold> PM </bold></text>
<text font_bg = '255,255,255'>
Hospital  <bold> Account </bold></text>
<text font_bg = '255,255,255'>
Name Acct  <bold> ID </bold>Class Status 505133244 Outpatient Closed </text>
<text font_bg = '255,255,255'>
 <bold> Account </bold> <bold> Information </bold></text>
<table>
<tr>Hospital Account Primary Payor Affiliated Recurring Accounts Combined from HAR

</tr>
<tr>505133244 - BCBS KC None None

</tr>
<tr>[503200702]


</tr>
</table>
<text font_bg = '244,250,255'>
 <bold> Admission </bold> <bold> Diagnoses </bold>/  <bold> Reasons </bold>for  <bold> Visit </bold>(ICD-10-CM) Code Name Comments G54.7 Phantom limb syndrome without pain </text>
<text font_bg = '255,255,255'>
G62.0 Drug-induced polyneuropathy T45.1X5A_ Adverse  <bold> effect </bold>of antineoplastic and immunosuppressive drugs, initial </text>
<table>
<tr>encounter

</tr>
<tr>G89.4 Chronic pain syndrome

</tr>
<tr>M79.2 Neuralgia and neuritis, unspecified

</tr>
<tr>F11.90 Opioid use, unspecified, uncomplicated


</tr>
</table>
<text font_bg = '255,255,255'>
 <bold> Final </bold>Diagnoses (ICD-10-CM) </text>
<table>
<tr>Affects

</tr>
<tr>Principal Code Name POA CC HAC DRG

</tr>
<tr>[P] G54.7 Phantom limb syndrome without pain

</tr>
<tr>G62.0 Drug-induced polyneuropathy


</tr>
</table>
<text font_bg = '255,255,255'>
T45.1X5A Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter </text>
<table>
<tr>G89.4 Chronic pain syndrome

</tr>
<tr>M79.2 Neuralgia and neuritis, unspecified

</tr>
<tr>F11.90 Opioid use, unspecified, uncomplicated


</tr>
</table>
<text font_bg = '255,255,255'>
 <bold> CPT®/HCPCS </bold> <bold> Codes </bold></text>
<text font_bg = '255,255,255'>
 <bold> PL </bold>(MR # 1388862) Printed at 6/6/17 12:43 PM Page 11 of 11 </text>
</page22>
</document>
